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Previous antiretroviral drug use 
compromises standard first-line 
HIV therapy and is mediated 
through drug-resistance
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T. Sonia Boender  1,10, Pascale Ondoa1,11, Kim C. E. Sigaloff1, Denise Naniche12, 
Tobias F. Rinke de Wit1 & Raph L. Hamers1,13
In ART programs in sub-Saharan Africa, a growing proportion of HIV-infected persons initiating first-line 
antiretroviral therapy (ART) have a history of prior antiretroviral drug use (PAU). We assessed the effect 
of PAU on the risk of pre-treatment drug resistance (PDR) and virological failure (VF) in a multicountry 
cohort of HIV-infected adults initiated on a standard non-nucleoside reverse transcriptase inhibitor 
(NNRTI)-based first-line ART. Multivariate logistic regression was used to assess the associations 
between PAU, PDR and VF (defined as viral load ≥400 cps/mL). Causal mediation analysis was used to 
assess the proportion of the effect of PAU on VF that could be eliminated by intervening on PDR. Of 
2737 participants, 122 (4.5%) had a history of PAU. Participants with PAU had a 7.2-fold (95% CI 4.4–
11.7) risk of carrying PDR and a 3.1-fold (95% CI 1.6–6.1) increased risk of VF, compared to antiretroviral-
naïve participants. Controlling for PDR would eliminate nearly half the effect of PAU on the risk of VF. 
Patients with a history of PAU are at increased risk of ART failure, which is to a large extent attributable 
to PDR. These findings support the recent WHO recommendations for use of differentiated, non-NNRTI-
based empiric first-line therapy in patients with PAU.
In low and middle-income countries (LMICs), antiretroviral treatment (ART) regimens to treat HIV-1 infec-
tions are standardized under the WHO-defined public health approach1. Although reliable data are limited, ART 
programs in sub-Saharan Africa have reported that between 10 and 25% of first-line ART initiators have pre-
viously used antiretroviral drugs, either because they re-started ART after disengaging from care, or they used 
short-course antiretrovirals through prevention of mother-to-child transmission (PMTCT) programs, or pre- or 
post-exposure prophylaxis2.
People with previous antiretroviral drug use (denoted PAU) are at an increased risk of having drug-resistant 
HIV before starting ART (denoted pre-treatment drug resistance, PDR)2,3, which impairs response to standard 
non-nucleoside reverse transcriptase inhibitor (NNRTI)-based first-line ART4–6. However, for patients with PAU, 
few studies to date have evaluated the response to standard first-line ART or optimal management7. The vast 
majority of LMICs provide standard first-line therapy regardless of antiretroviral history or PDR testing1,8.
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This study aimed to investigate the effects of PAU on PDR and virological failure (VF) in a multi-country 
cohort in sub-Saharan Africa, and the extent of which this effect could be eliminated by intervening on PDR.
Methods
Study design and population. The Pan-African Studies to Evaluate Resistance Monitoring (PASER-M) 
study was a prospective multi-country cohort including 13 sites in 6 countries (Kenya, Nigeria, South Africa, 
Uganda, Zambia, Zimbabwe), as profiled elsewhere5, conducted between 2007 and 2014. All participants were 
followed up according to local standard-of-care guidelines. The present study included all participants who ini-
tiated first-line ART containing an NNRTI plus two NRTIs. Retrospective viral load (VL) testing was performed 
before ART initiation and annually after ART initiation. Participants provided written informed consent at study 
enrolment. The study was approved by the appropriate research ethics committees at all collaborating sites and 
the Amsterdam UMC, University of Amsterdam, Institutional Review Board. The study was performed in accord-
ance with relevant guidelines and regulations.
Virological analysis. VL and PDR were retrospectively measured at either of two reference laboratories 
in Uganda and South Africa5. Sanger sequencing of the pol gene was performed if VL ≥ 1000 cps/ml using 
in-house assays. PDR was defined as the presence of ≥1 major drug resistance mutation (DRM) included in the 
International Antiviral Society–USA mutation list of December 2017 that are associated with any NRTI or the 
NNRTIs nevirapine or efavirenz9, plus the revertant mutations at codon 215 (A/C/D/E/N/S/V)10.
Statistical analyses. Logistic regression analysis. Multivariate logistic regression with robust standard errors 
to account for clustering of observations within sites was used to assess the association between PAU and PDR 
and VF at month 12, defined as VL ≥ 400 cps/mL or a switch to second-line ART due to treatment failure up to 12 
months. PAU was defined both as a dichotomous and a categorical variable according to type as follows: none, ART 
(standard triple ARV combinations), single-dose nevirapine (sdNVP) for PMTCT, or other ARV combinations 
(including mono/dual therapy). Models were adjusted for potential confounders, which were selected stepwise from 
the following list of independent variables: age, sex, country, calendar year of treatment initiation, type of NNRTI 
and NRTI, PDR, pretreatment VL and CD4 cell count, and the 12 months average of 30-day self-reported adherence. 
Subsequently, we investigated PDR as a potential effect modifier of the association between PAU and VF by includ-
ing an interaction term in the model, and stratifying the model according to the presence/absence of PDR.
Causal mediation analysis. We also investigated PDR as a potential intermediate on the causal pathway of the 
association between PAU and VF using causal mediation analysis (Fig. 1)11. We calculated: 1) the proportion 
mediated, a measure that determines how much of the effect of the exposure (PAU) on the outcome (VF) is due 
to the effect of the exposure (PAU) on the intermediate (PDR). Proportion mediated is calculated as the ratio 
of natural indirect effect (NIE, effect of PDR on VF assuming all participants had PAU) to the total effect (TE), 
where TE = NIE + NDE (natural direct effects, effect of PAU on VF assuming PDR prevalence is similar in per-
sons with/without PAU); 2) the proportion eliminated, a measure that determines the effect of the exposure (PAU) 
on the outcome (VF), that could be eliminated by intervening on the intermediate (PDR). Conceptually, this is 
the scenario where each patient receives a fully active ART regimen, either empirically or guided by PDR testing; 
therefore, by intervening on PDR we could eliminate a part of the effect of PAU on VF. Proportion eliminated is 
calculated as TE-CDE(m =0 )/TE, where CDE (controlled direct effects) is the effect of PAU on VF while fixing 
the intermediate PDR (m) to level 0. The causal mediation analysis was done using the paramed syntax in Stata 
with log-linear regression, assuming interaction12.
Figure 1. Direct acyclic graph (DAG) showing the relationship between prior ARV use, pre-treatment drug 
resistance and virological failure. P represents direct effects of prior ARV use on virological failure. Q represents 
indirect effects of prior ARV use on virological failure mediated through pre-treatment drug resistance. R represents 
confounders of the association between prior ARV use and virological failure: age and sex. S represents confounders 
of the association between pre-treatment drug resistance and virological failure that are affected by prior ARV use: 
pre-treatment viral load, CD4 cell counts and adherence. T represents confounders of the association between pre-
treatment drug resistance and virological failure not included in S: type of initial antiretroviral treatment (NNRTI and 
NRTI) initiated and calendar year of treatment initiation. U represents unmeasured confounders. We note that the 
DAG is only a simple illustration and this may exclude complex relationships interacting between prior ARV use/pre-
treatment drug resistance/virological failure and their confounders.
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Sensitivity analyses. We performed the following sensitivity analyses to confirm the robustness of the associ-
ations: (1) We used a higher VL threshold of ≥ 1000 cps/mL to define VF (WHO definition)1; (2) We assessed 
the effect of PAU on acquired drug resistance (ADR) at 12 months for patients with VF ≥ 1000 cps/mL; (3) We 
further elucidated the effects of PDR on VF by restricting its definition to the presence of NNRTI-resistance 
(NNRTI-PDR); (4) We assessed the longer-term effect of PAU on VF (up to 24 months follow-up).
Results
Patient characteristics. Of the 2737 participants initiating ART, 122 (4.5%) had a documented history of 
PAU and 2615 (95.5%) were antiretroviral-naive; 23 (0.8%) participants were excluded because information on 
PAU was missing (Table 1). PAU comprised: ART (50%, 61/122), sdNVP (32%, 39/122), and other ARV combi-
nations (18%, 22/122) (Table S1). Compared to antiretroviral-naïve participants, those with PAU were more likely 
to be female (5.9% vs 2.6%, p < 0.001), younger (median age 34.7 years [IQR 29.1–40.5] vs 37.0 [IQR 32.0–43.3], 
p < 0.001) with higher pre-treatment CD4 cell counts (median 177 [IQR 147–202] vs 133 [IQR 62–203] cells/μl, 
p = 0.0017) (Table 1). Females were more frequently exposed to sdNVP (2.6% vs 0%, p < 0.001) and other ARV 
combinations (1.3% vs 0.2%, p = 0.001), but not to ART (2.2% vs 2.4%, p = 0.813). The proportion of participants 
who had an average adherence level ≥95% did not differ between patients with (86.5%) or without (86.4%) PAU 
(p = 0.977).
Effect of PAU on PDR. 2557/2714 (94.2%) participants had a PDR test performed, of whom 144 (5.6%) 
had PDR, with 115/2442 (4.7%) in antiretroviral-naïve participants and 29/115 (25.2%) among those with PAU 
(p < 0.001) (Fig. 2). The proportion of participants who carried any DRM, NNRTI-resistance, NRTI-resistance 
and dual-class resistance was: 29.1%, 27.3%, 12.7%, 10.9%, respectively, after ART; 28.6%, 14.3%, 19.1%, 4.8%, 
respectively, after other ARV combinations; 18.0%, 12.8%, 5.1%, 0.0%, respectively, after sdNVP; and 4.7%, 
3.6%, 2.1%, 1.1%, respectively, for those who were antiretroviral-naive. In the adjusted analysis, the odds of 
PDR was 7.2-fold (95% CI 4.4–11.7; p < 0.001) higher in participants with PAU, compared to those who were 
antiretroviral-naive; and varied with the type of PAU: aOR 15.1 (95% CI, 5.3–42.5; p < 0.001) after other ARV 
combinations, 9.1 (95% CI 4.8–17.2; p < 0.001) after ART, and 3.3 (95% CI 1.4–8.1; p = 0.008) after sdNVP 
(Table 2).
Effect of PAU on VF. Multivariable regression analysis. 200/2031 (9.8%) participants who had a VL test 
result at 12 months experienced VF while 9 other patients had been switched to second-line treatment before 12 
months. Of these 20/86 (23.3%) patients had PAU and 190/1953 (9.7%) were antiretroviral-naive (p ≤ 0.001). In 
the adjusted analysis, the odds of VF was 3.1-fold (95% CI 1.6–6.1; p = 0.001) higher in participants with PAU, 
compared to those who were antiretroviral-naive; and varied with the type of PAU: aOR 3.1 (95% CI 0.9–11.0; 
Characteristic
Prior ARV use 
N = 122
ARV naïve 
N = 2592 P-value
Age (years) Median IQR 34.7 (29.1–40.5) 37.0 (32.0–43.3) <0.001
Sex, n (%)
  Female 29 (23.8) 1108 (42.8) <0.001
  Male 93 (76.2) 1484 (57.3)
VL (log10) Median 
(IQR) 4.9 (4.1–5.6) 5.2 (4.4–5.6) 0.240
CD4 (Log10) Median 
(IQR) 177 (147–202) 133 (62–203) 0.0017
WHO clinical stage 0.275
I/II 54 (44.3) 1019 (39.3)
III/IV 68 (55.7) 1573 (60.7)
Type of initial NNRTI
  EFV 73 (59.8) 1545 (59.6) 0.964
  NVP 49 (40.2) 1046 (40.4)
Type of initial NRTI backbone
  TDF + XTC 43 (35.3) 866 (33.4) 0.790
  d4T + 3TC 29 (23.8) 695 (26.8)
  ABC + 3TC 2 (1.6) 66 (2.6)
  ZDV + 3TC 48 (39.3) 964 (37.2)
†ART adherence 0.977
  ≥95% 96 (86.5) 2044 (86.4)
  <95% 15 (13.5) 322 (13.6)
Table 1. Baseline characteristics of patients with and without prior ARV use. Data are presented as n (%), 
unless stated otherwise. 3TC, lamivudine; ABC, abacavir; ART, antiretroviral therapy; d4T, stavudine; EFV, 
efavirenz; NVP, nevirapine; TDF, tenofovir; VL: viral load; XTC, lamivudine or emtricitabine; ZDV, zidovudine. 
†Mean adherence measured as 30-day self-reported adherence over 12 months.
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p = 0.088) after sdNVP, 3.9 (95% CI 1.6–9.1; p = 0.002) after ART, and 1.4 (95% CI 0.5–5.0; p = 0.562) after other 
ARV combinations (Table 2).
The association between PAU and VF was similar when using a higher VL threshold (aOR 3.5, 95% CI 1.-7.4; 
p = 0.001) (sensitivity analysis 1; Table S2). Genotypic results were available for 130/182 participants with a viral 
load >1000 cps/mL at 12 month, 95 (73%) of which had one or more major drug-resistance mutations. Compared 
with antiretroviral-naive participants, people with PAU had an increased risk of ADR (aOR 3.5, 95% CI 1.3–9.2; 
p = 0·010) (sensitivity analysis 2; Table S3).
Effect modification by PDR. In the regression model with interaction term, there was no evidence that PDR was 
an effect modifier of the association between PAU and VF (p for interaction = 0.485) (Table 2). Similarly, there was 
no evidence for interaction when we used a higher VL threshold (p for interaction = 0.432) (sensitivity analysis 1; 
Table S2) or when PDR was restricted to NNRTI-PDR (p for interaction = 0.451) (sensitivity analysis 3; Table S4).
Causal mediation by PDR. Table 1 summarizes the causal mediation analysis. The total effects of PAU on the 
risk of VF was aOR 4.8 (95% CI 2.3–10.0; p < 0.001). The proportion of the effect of PAU on VF mediated through 
PDR was 38%. The controlled direct effects of PAU, when fixing PDR = 0, remained statistically significantly 
associated with VF (aOR 2.7, 95% CI 1.5–5.0; p = 0.002). The proportion of the effect of PAU on VF that could be 
eliminated by intervening on PDR was 48%.
Compared to the main analysis, a VL threshold of >1000 cps/ml to define VF resulted in a slight reduction 
in the proportion mediated (33%) and an increase in the proportion eliminated (51%%) (sensitivity analysis 1; 
Table S2), and a restricted definition of NNRTI-PDR resulted in a similar proportion mediated (36%) and an 
increase in the proportion eliminated (63%) (sensitivity analysis 3; Table S4).
Long-term effect of PAU on VF (sensitivity analysis 4). 192/1838 (10%) participants who had a VL test result at 24 
months experienced VF while 53 other patients had been switched to second-line treatment before 24 months. Of 
these 25/73 (34.2%) patients had PAU and 243/1818 (13.4%) were antiretroviral-naive (p ≤ 0.001). In the adjusted 
analysis, the odds of VF was 4.3-fold (95% CI 2.3–8.2; p < 0.001) higher in participants with PAU, compared to 
those antiretroviral-naive; and varied with the type of PAU: aOR 2.9 (95% CI 0.8–10.4; p = 0.110) after sdNVP, 
6.7 (95% CI 3.0–14.6; p < 0.001) after ART, and 3.0 (95% CI 1.0–9.0; p = 0.055) after other ARV combinations 
(Table S5).
Causal mediation analysis showed that the proportion of the effect of PAU on VF mediated through PDR was 
24% and the proportion of the effect of PAU on VF that could be eliminated by intervening on PDR was 29%.
Discussion
This prospective study among HIV-infected adults in sub-Saharan Africa starting first-line NNRTI-based ART 
found that persons who had a history of PAU, i.e. ART or sdNVP for PMTCT, were seven times more likely to 
have PDR, and three times more likely to experience VF within the first year of NNRTI-based ART, compared to 
those who were antiretroviral-naïve at ART initiation.
A causal mediation analysis provided two important additional insights. First, the pathway through the inter-
mediate PDR was estimated to explain about 38% of the operation of the effect of PAU on VF. Conceptually, 
this means that the higher VF rates found in patients with PAU could partially be attributed to the presence of 
PDR, predominantly associated with the drug class of NNRTIs. We speculate that the residual effect of PAU 
Figure 2. Patterns of drug resistance mutations in participants with and without prior ARV use Of all DRMs 
detected, 25.2% occurred in the participants with PAU. The proportion of participants who carried NNRTI, 
NRTI and dual NNRTI + NRTI resistance was 20.0%, 11.3% and 6.1% respectively for those with PAU and 
3.6%, 2.1%, 1.1% for antiretroviral-naïve participants respectively.
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could partially be attributed to unmeasured NNRTI-resistant minority variants, since the limited sensitivity of 
Sanger-based sequencing to detect minority virus populations may have resulted in an underestimation of the 
total effect of PDR. NNRTI-resistant minority variants have previously been shown to be associated with VF13, 
with higher impact among patients with PAU14,15.
Second, if we could eliminate the effect of the intermediate PDR on VF, the effect of PAU on VF is estimated to 
be reduced by half or more. Conceptually, this means that the use of an alternative fully-active first-line regimen 
in patients with PAU could half the number of failures that are attributable to PAU. This could be achieved by 
adopting either of two strategies in patients with PAU: the use of individualized PDR testing to guide the choice 
of first-line treatment, or a change of standard first-line regimen that is non-NNRTI-based (e.g. dolutegravir). 
The latter option has the advantage of addressing the potential residual impact of PAU on VF due to unmeasured 
minority resistant variants in absence of more sensitive resistance tests.
Previous studies on this topic are limited. Across seven WHO-led national surveys in LMICs, PDR was found 
to be considerably higher among persons with PAU (22%) than among antiretroviral-naive people (8%)2. A 
cross-sectional study in Nigeria found that patients with PAU were four times more likely to experience VF when 
initiated on NNRTI-based therapy7.
Our findings emphasize the importance of thorough assessment of previous antiretroviral history before 
ART initiation, and the use of non-NNRTI-based empiric first-line therapy (e.g. based on the integrase-inhibitor 
dolutegravir) in line with the latest WHO guidelines (July 2017)8. Our findings also provide further support to 
lifelong ART in childbearing women (PMTCT option B+) to avoid the risks associated with cycles of ART stop-
ping and re-starting.
Our findings suggest that potential interventions to eliminate the effect of PDR (i.e. by providing an alter-






Effect of prior ARV use on PDRa
Any prior ARV use
No 2534 288 1.0 1.0
Yes 119 29 6.8 (4.3–10.8) <0.001 7.2 (4.4–11.7) <0.001
Type of prior ARV use
None 2534 288 1.0 1.0
ART 58 16 8.3 (4.5–15.3) <0.001 9.1 (4.8–17.2) <0.001
sdNVP 39 7 4.4 (1.9–10.2) 0.001 3.3 (1.4–8.1) 0.008
Other 22 6 8.1 (3.1–21.2) <0.001 15.1 (5.3–42.5) <0.001
Effect of prior ARV use on VFb
Any prior ARV use
No 1953 190 1.0 1.0
Yes 86 20 2.7 (1.6–4.6) <0.001 3.1 (1.6–6.1 0.001
Type of prior ARV use
None 1953 190 1.0 1.0
ART 44 13 3.6 (1.7–7.7) 0.001 3.9 (1.6–9.1) 0.002
sdNVP 29 5 1.9 (0.6–6.0) 0.256 3.1 (0.9–11.0) 0.088
Other 13 2 1.7 (0.6–4.7) 0.317 1.4 (0.5–4.0) 0.562
Logistic regression model including 
interaction term (prior ARV use* PDR)c 0.485
PDR as intermediate on causal pathwayd Causal mediation analysis
Natural direct effects (NDE) 2.1 (1.2–3.8.) 0.013 2.7 (1.5–5.0) 0.002
Natural indirect effects (NIE) 1.4 (0.9–2.3) 0.1340 1.8 (1.0–3.1) 0.059
Controlled direct effect (CDE) 2.1 (1.1–4.1) 0.031 2.5 (1.2–5.1) 0.010
Total effects (TE)e 3.0(1.6–5.7) 0.001 4.8 (2.3–10.0) <0.001
Proportion mediated PM = NIE/TE = 38%
Proportion eliminated PE = (TE − CDE)/TE = 48%
Table 2. Associations between prior antiretroviral drug use, pre-treatment drug resistance and virological 
failure. Abbreviations: ART, antiretroviral combination therapy; ARV, antiretroviral; PDR, pretreatment drug 
resistance; sdNVP, single-dose nevirapine for PMTCT; VF, virological failure’; NIE, natural indirect effects; 
NDE, natural direct effects; CDE, controlled direct effects; TE, total effects. aAdjusted for age, sex, pre-treatment 
CD4 count, pre-treatment viral load, WHO clinical stage, calendar year of ART initiation, country. bAdjusted 
for age, sex, pre-treatment CD4 count, pre-treatment drug resistance, type of ART, calendar year of ART 
initiation and adherence. cAdjusted for age, sex, pre-treatment CD4 count, type of ART, calendar year of ART 
initiation and adherence. dAdjusted for age, sex, pre-treatment CD4 counts, pre-treatment viral load, type of 
ART, calendar year of ART initiation and adherence. eodds ratio for TE i.e. ORTE = ORNDE*ORNIE.
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particularly substantive in reducing early VF during the first year of ART (48% risk reduction up to 12 months). 
However, in the longer term the impact may be more modest (29% risk reduction up to 24 months). These 
findings suggest that in the longer term the influence of PDR may be waning and that other factors explain the 
continuous impact of PAU on the risk of VF. We hypothesize that unaddressed factors associated with the initial 
default from care (hence the presence of PAU) may be undermining succesful adherence to long-term treatment, 
underscoring the need for enhanced adherence interventions for patients with PAU.
Strengths of the study were its prospective design, large sample, and the availibility of combined data on PAU, 
PDR and virological outcomes. The setting of routine ART programs enhanced the generalizibility of the results 
to other LMICs.
Study limitations were the lack of detailed PAU histories, precluding an in-depth analysis of attributes such as 
adherence, dosage, timing and duration, and the use of patient self-report and medical records to document PAU 
histories, with potential for recall and desirability bias16. This could have resulted in overall underestimation in 
the effect of PAU on VF. These limitations highlight the importance of enhancing electronic patient information 
systems that can link patient data across ART delivery sites.
In conclusion, patients with a history of PAU in African ART programs are at increased risk of ART failure, 
which is to a large extent attributable to the presence of PDR. To help meet the third of the UNAIDS global 
targets (i.e. ensuring viral suppression in 90% of people on ART), the choice of first-line ART regimens should 
be guided by a thorough assessment of antiretroviral history. Patients with PAU should receive differentiated, 
non-NNRTI-based empiric first-line therapy as recommended by the latest WHO guidelines.
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